AtaiBeckley Inc.

What they do

AtaiBeckley develops investigational psychedelic-based neuroplastogens for treatment-resistant depression (TRD) and social anxiety disorder (SAD). Its core programs are BPL-003 (intranasal mebufotenin benzoate for TRD), VLS-01 (buccal DMT film for TRD), EMP-01 (oral R-MDMA for SAD), and a discovery program for non-hallucinogenic 5-HT2AR agonists. The company has no approved products and has not generated commercial product revenue.

Revenue drivers

• Research and development services revenue — The company reported annual revenue of $4.1 million in 2025 versus $308,000 in 2024; quarterly revenue was $1.6 million in Q1 2025, $719,000 in Q2 2025, $954,000 in Q1 2026 and $1.7 million in Q2 2026.
• Product candidates (pre-revenue) — BPL-003, VLS-01 and EMP-01 are clinical-stage programs with no approved products, so they generate no product revenue.
• Pipeline and IP — The company states intellectual property development has been a key strategic component since inception, alongside novel chemical entity discovery.

Recent performance

For full-year 2025, AtaiBeckley reported revenue of $4.1 million and a net loss of $660.0 million, or $2.91 diluted EPS, versus a 2024 net loss of $149.3 million, or $0.93 diluted EPS. Operating cash flow was negative $102.7 million in 2025 and negative $82.4 million in 2024. As of June 30, 2026, the company reported total assets of $264.8 million, total liabilities of $88.4 million, shareholder equity of $176.4 million and cash and equivalents of $168.8 million. The company reported $209.9 million in cash as of March 31, 2026, per its Q1 2026 earnings release.

Strategy

Management's stated near-term priority is initiating the Phase 3 ReConnection program for BPL-003 in TRD in Q2 2026, comprising two pivotal studies of approximately 350 and 230 patients with a primary endpoint of change in MADRS total score at Week 4. VLS-01 is progressing toward Elumina Phase 2 topline results in Q4 2026, and BPL-003 Phase 2a Part 4 initial data is also expected in Q4 2026. The company says its cash position is expected to fund operations through anticipated BPL-003 Phase 3 topline readouts, with runway into 2029. It also cites index inclusion in the S&P Biotechnology Select Industry Index and CRSP U.S. indices during Q1 2026.

Risks

• No approved products or commercial revenue — The company is clinical-stage with no approved products and has not generated commercial product revenue, and it expects losses for the foreseeable future.
• Significant and growing losses — Net loss attributable to stockholders was $660.0 million in 2025 and $149.3 million in 2024, with operating cash outflows of $102.7 million and $82.4 million respectively.
• Need for additional capital — The company has financed operations predominantly through equity and debt financings and will need capital to fund development and commercialization.
• Clinical and regulatory uncertainty — Revenue from any product candidate depends on obtaining regulatory approval and on market size, pricing, physician and patient acceptance and reimbursement.

Outlook

Management states that BPL-003 Phase 3 topline readouts are anticipated in early 2029, with Phase 3 initiation targeted for Q2 2026. VLS-01 Elumina Phase 2 topline results and BPL-003 Phase 2a Part 4 initial data are anticipated in Q4 2026. The company says its cash position is expected to fund operations through the anticipated BPL-003 Phase 3 topline readouts, with runway into 2029.